Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group. Altaweel MM, et al. Among authors: melamud a. Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11. Ophthalmology. 2015. PMID: 25307130 Free PMC article. Clinical Trial.
Reply.
Mathai M, Godwin KS, Albarracin J, Levinson J, Broderick K, Melamud A. Mathai M, et al. Among authors: melamud a. Retina. 2023 Sep 1;43(9):e55-e56. doi: 10.1097/IAE.0000000000003854. Retina. 2023. PMID: 37263183 No abstract available.
Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials.
Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Xue K, et al. Ophthalmol Retina. 2023 Jul;7(7):564-572. doi: 10.1016/j.oret.2023.02.008. Epub 2023 Feb 19. Ophthalmol Retina. 2023. PMID: 36803692 Clinical Trial.
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Core JQ, et al. Ophthalmol Retina. 2022 Sep;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. Epub 2022 Apr 9. Ophthalmol Retina. 2022. PMID: 35405352 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
72 results